Remifentanil Preconditioning Reduces Hepatic Ischemia–Reperfusion Injury in Rats via Inducible Nitric Oxide Synthase Expression
- 1 May 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anesthesiology
- Vol. 114 (5), 1036-1047
- https://doi.org/10.1097/aln.0b013e3182104956
Abstract
Background: Opioid preconditioning against ischemia reperfusion injury has been well studied in myocardial and neuronal tissues. The objective of this study was to determine whether remifentanil could attenuate hepatic injury and to investigate the mechanisms. Methods: A rat model of hepatic ischemia reperfusion injury and a hepatocyte hypoxia reoxygenation (HR) injury model were used, respectively, in two series of experiments. Remifentanil was administered before ischemia or hypoxia and the experiments were repeated with previous administration of naloxone, L-arginine and N-ω-nitro-L-arginine methyl ester, a nonselective opioid receptor antagonist, a nitric oxide donor, and nitric oxide synthase (NOS) inhibitor, respectively. Serum aminotransferase, cytokines, and hepatic lipid peroxidation were measured. Histopathology examination and apoptotic cell detection were assessed. For the in vitro study, cell viability, intracellular nitric oxide, apoptosis, and NOS expression were evaluated. Results: Remifentanil and L-arginine pretreatment reduced concentrations of serum aminotransferases and cytokines, decreased the concentrations of hepatic malondialdehyde and myeloperoxidase activity, and increased superoxide dismutase, nitric oxide, and inducible NOS expression in vivo. Decreased histologic damage and apoptosis were also seen in these two groups. These changes were prevented by previous administration of N-ω-nitro-L-arginine methyl ester but not naloxone. There was an increase in inducible NOS protein expression but not endogenous NOS in remifentanil and L-arginine pretreated groups compared with control, naloxone, and N-ω-nitro-L-arginine methyl ester groups. Conclusion: Pretreatment with remifentanil can attenuate liver injury both in vivo and in vitro. Inducible NOS but not opioid receptors partly mediate this effect by exhausting reactive oxygen species and attenuating the inflammatory response.Keywords
This publication has 41 references indexed in Scilit:
- Remifentanil Reduces the Release of Biochemical Markers of Myocardial Damage After Coronary Artery Bypass Surgery: A Randomized TrialJournal of Cardiothoracic and Vascular Anesthesia, 2010
- Remifentanil post‐conditioning attenuates cardiac ischemia–reperfusion injury via κ or δ opioid receptor activationActa Anaesthesiologica Scandinavica, 2010
- Protective effects of remifentanil on septic miceMolecular Biology Reports, 2009
- Neuroprotection and functional recovery conferred by administration of kappa- and delta1-opioid agonists in a rat model of global ischemiaPhysiology & Behavior, 2008
- Role of Reactive Oxygen Species in Mediating Hepatic Ischemia-Reperfusion Injury and Its Therapeutic Applications in Liver TransplantationTransplantation Proceedings, 2007
- Opioid receptor-independent protection of ischemic rat hepatocytes by morphineBiochemical and Biophysical Research Communications, 2006
- La protection myocardique contre les lésions d’ischémie-reperfusion par des anesthésiques: Une mise à jour pour les anesthésiologistesCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2002
- Effects of endotoxin tolerance on liver function after hepatic ischemia/reperfusion injury in the ratCritical Care Medicine, 2002
- Hepatic ischemia-reperfusion injuryThe American Journal of Surgery, 2001
- Tissue Distribution of Opioid Receptor Gene Expression in the RatBiochemical and Biophysical Research Communications, 1996